Genmab A/S (NASDAQ:GMAB) Given Average Recommendation of "Hold" by Analysts

Shares of Genmab A/S (NASDAQ:GMAB - Get Free Report) have been given an average rating of "Hold" by the thirteen brokerages that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $45.20.

Several equities analysts have recently commented on GMAB shares. Royal Bank of Canada upgraded Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. BTIG Research raised their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a "buy" rating in a report on Thursday, June 27th. Truist Financial dropped their target price on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research report on Monday. Morgan Stanley reiterated an "equal weight" rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday. Finally, JPMorgan Chase & Co. restated a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently added to or reduced their stakes in GMAB. International Assets Investment Management LLC bought a new stake in shares of Genmab A/S during the fourth quarter valued at approximately $393,000. M&T Bank Corp raised its stake in Genmab A/S by 87.8% during the 4th quarter. M&T Bank Corp now owns 15,432 shares of the company's stock valued at $492,000 after acquiring an additional 7,213 shares in the last quarter. Principal Securities Inc. acquired a new position in Genmab A/S during the 4th quarter worth $77,000. Envestnet Portfolio Solutions Inc. grew its stake in shares of Genmab A/S by 32.7% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 27,122 shares of the company's stock worth $864,000 after purchasing an additional 6,681 shares in the last quarter. Finally, Torray Investment Partners LLC increased its holdings in shares of Genmab A/S by 2.6% during the fourth quarter. Torray Investment Partners LLC now owns 107,201 shares of the company's stock valued at $3,413,000 after purchasing an additional 2,685 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Genmab A/S stock traded down $0.57 during midday trading on Wednesday, hitting $26.93. 338,331 shares of the stock were exchanged, compared to its average volume of 574,078. The company has a 50 day moving average price of $27.19 and a two-hundred day moving average price of $28.10. The firm has a market cap of $17.81 billion, a P/E ratio of 22.44, a P/E/G ratio of 0.87 and a beta of 0.99. Genmab A/S has a 1 year low of $24.53 and a 1 year high of $38.80.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). The business had revenue of $779.50 million for the quarter, compared to analysts' expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. As a group, analysts predict that Genmab A/S will post 1.21 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.